Metabomed
Target-inhibiting Anticancer Drugs
Company Overview
Snapshot
Founded in October 2013 by Eyal Gottlieb and Simone Botti, Metabomed operates with 1–10 employees. The company has raised $30.5M across 4 funding rounds from 7 investors. In May 2024, Metabomed ceased operations.
Business overview
Metabomed is a drug-discovery company specializing in cancer metabolism. The company leverages a proprietary target-identification platform that integrates computational biology and metabolomics to develop drugs. Its core technology focuses on inhibiting targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells. This approach aims to create highly selective anticancer drugs capable of eliminating cancer cells without harming normal cells, serving the biopharmaceutical and oncology markets within the Health Tech & Life Sciences sector.
Strategic signal
In May 2024, Metabomed ceased operations, indicating a significant and definitive shift in its corporate trajectory. This event signals to investors and innovation teams that the company is no longer actively pursuing its drug discovery and development initiatives in cancer metabolism.
Log in to access full profile ›Company Intelligence Q&A
- What is Metabomed's current operational status?
- Metabomed ceased operations in May 2024.
- When was Metabomed founded and by whom?
- Metabomed was founded in October 2013 by Eyal Gottlieb and Simone Botti.
- How much capital has Metabomed raised in total?
- Metabomed has raised a total of $30.5M across its funding rounds.
- Who was appointed CEO of Metabomed in September 2020?
- In September 2020, Ali Fattaey, Ph.D. was appointed as the Chief Executive Officer of Metabomed.
- Which investors participated in Metabomed's December 2019 funding round?
- In December 2019, Metabomed received funding from investors including Yonjin Ventures.